The latest price target for Keros Therapeutics (NASDAQ:KROS) was reported by Oppenheimer on December 16, 2024. The analyst firm set a price target for $63.00 expecting KROS to rise to within 12 months (a possible 270.37% upside). 23 analyst firms have reported ratings in the last year.

The latest analyst rating for Keros Therapeutics (NASDAQ:KROS) was provided by Oppenheimer, and Keros Therapeutics maintained their outperform rating.

There is no last upgrade for Keros Therapeutics

The last downgrade for Keros Therapeutics Inc happened on December 16, 2024 when Guggenheim changed their price target from N/A to N/A for Keros Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Keros Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Keros Therapeutics was filed on December 16, 2024 so you should expect the next rating to be made available sometime around December 16, 2025.

While ratings are subjective and will change, the latest Keros Therapeutics (KROS) rating was a maintained with a price target of $102.00 to $63.00. The current price Keros Therapeutics (KROS) is trading at is $17.01, which is out of the analyst’s predicted range.